A cost-effectiveness study comparing the as-needed use of formoterol (Oxis®) and terbutaline (Bricanyl®) in patients with moderate to severe asthma

Abstract

This study evaluated the economic and health-related consequences of the as-needed use of a long-actingβ2 -agonist with fast onset (formoterol, Oxis®Turbuhaler®4·5μ g) versus a short-acting β2-agonist (terbutaline, Bricanyl®Turbuhaler®0·5 mg) in patients with moderate to severe asthma. A multi-national (Sweden, Norway, The Netherlands and Greece), multi-centre (35 centres), randomized, double-blind clinical trial was conducted using 362 patients on inhaled steroids during a 12-week period. The effectiveness results were pooled and the total costs included estimates for β2-agonists, inhaled steroids, oral steroids, physician visits and sick-leave. The 182 patients in the formoterol group had 14404 days of exposure and 29 severe exacerbations, and the 180 patients in the terbutaline group had 13655 days of exposure and 48 severe exacerbations. The terbutaline group had 62% more severe exacerbations than the formoterol group (P=0·039), based on exposure time. Per patient, the calculated total costs were SEK 3386 for the formoterol group and SEK 3709 for the terbutaline group over the 12-week period. The conclusion is that the use of Oxis®Turbuhaler®instead of Bricanyl®Turbuhaler®for as-needed treatment is a more effective treatment generating cost savings from a societal perspective.